MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpeds.2014.01.029

Медицинская библиотека · The Journal of pediatrics · 2014

Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.

He Yang, Brunstrom-Hernandez Janice E, Thio Liu Lin, Lackey Shellie, Gaebler-Spira Deborah, Kuroda Maxine M, Stashinko Elaine, Hoon Alexander H, Vargus-Adams Jilda, Stevenson Richard D, Lowenhaupt Stephanie, McLaughlin John F, Christensen Ana, Dosa Nienke P, Butler Maureen, Schwabe Aloysia, Lopez Christina, Roge Desiree, Kennedy Diane, Tilton Ann, Krach Linda E, Lewandowski Andrew, Dai Hongying, Gaedigk Andrea, Leeder J Steven, Jusko William J

Клиническое исследованиеСтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

OBJECTIVE

To characterize the population pharmacokinetics (PK) of oral baclofen and assess impact of patient-specific covariates in children with cerebral palsy (CP) in order to support its clinical use.

SUBJECTS

DESIGN

Children (2-17 years of age) with CP received a dose of titrated oral baclofen from 2.5 mg 3 times a day to a maximum tolerated dose of up to 20 mg 4 times a day. PK sampling followed titration of 10-12 weeks. Serial R- and S-baclofen plasma concentrations were measured for up to 16 hours in 49 subjects. Population PK modeling was performed using NONMEM 7.1 (ICON PLC; Ellicott City, Maryland).

RESULTS

R- and S-baclofen showed identical concentration-time profiles. Both baclofen enantiomers exhibited linear and dose/kg-proportional PK, and no sex differences were observed. Average baclofen terminal half-life was 4.5 hours. A 2-compartment PK model with linear elimination and transit absorption steps adequately described concentration-time profiles of both baclofen enantiomers. The mean population estimate of apparent clearance/F was 0.273 L/h/kg with 33.4% inter-individual variability (IIV), and the apparent volume of distribution (Vss/F) was 1.16 L/kg with 43.9% IIV. Delayed absorption was expressed by a mean transit time of 0.389 hours with 83.7% IIV. Body weight, a possible genetic factor, and age were determinants of apparent clearance in these children.

CONCLUSION

The PK of oral baclofen exhibited dose-proportionality and were adequately described by a 2-compartment model. Our population PK findings suggest that baclofen dosage can be based on body weight (2 mg/kg per day) and the current baclofen dose escalation strategy is appropriate in the treatment of children with CP older than 2 years of age.

Для цитирования: He Yang, Brunstrom-Hernandez Janice E, Thio Liu Lin, Lackey Shellie, Gaebler-Spira Deborah, Kuroda Maxine M, Stashinko Elaine, Hoon Alexander H, Vargus-Adams Jilda, Stevenson Richard D, Lowenhaupt Stephanie, McLaughlin John F, Christensen Ana, Dosa Nienke P, Butler Maureen, Schwabe Aloysia, Lopez Christina, Roge Desiree, Kennedy Diane, Tilton Ann, Krach Linda E, Lewandowski Andrew, Dai Hongying, Gaedigk Andrea, Leeder J Steven, Jusko William J. Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy.. The Journal of pediatrics. 2014. DOI: 10.1016/j.jpeds.2014.01.029.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.